Among HIV patients receiving well-organized care with free access to antiretroviral therapy, those who smoke lose more years of life to smoking than to HIV, according to a Danish study published in Clinical Infectious Diseases and available online. The findings highlight the importance of smoking cessation efforts in the long-term, integrated care of patients infected with HIV.
Marie Helleberg, MD, of Copenhagen University Hospital and colleagues estimated the effect of smoking on mortality, risk of death, and life expectancy, and the number of life years lost to smoking compared to years lost to HIV among nearly 3,000 HIV-infected patients treated in Denmark from 1995 to 2010. They also compared mortality associated with smoking between HIV patients and the country's background population. Where HIV care is integrated and antiretroviral therapy is available at no cost, "more than 60 percent of deaths among HIV patients are associated with smoking," rather than HIV, Dr. Helleberg said.
Estimated life expectancy differed significantly based on smoking status. A 35-year-old HIV patient who currently smokes had a life expectancy of 62.6 years, compared to 78.4 years for a nonsmoker infected with HIV. The loss of years of life associated with smoking was twice as high as that associated with HIV among HIV-infected patients. In addition, researchers found the excess mortality of HIV-infected smokers to be three times higher than that of individuals not infected with HIV.
"Our findings emphasize the importance of counseling HIV patients on smoking cessation as smoking may impact their life expectancy considerably more than the HIV infection itself," the study authors wrote. The results also underscore the importance of prioritizing interventions for stopping smoking in HIV patient care and for the general population. Smokers who stop see their risk of cardiovascular disease drop rather quickly, but they remain at increased risk of cancer until several years after quitting.
The emphasis on well-organized HIV care is crucial, according to Dr. Helleberg and her team. Continuing to smoke—or starting the habit—poses extra risks for patients with HIV. Patients who receive integrated care from a variety of health care professionals, including those who can help patients address lifestyle issues, can find support for decisions to stop smoking.
Infectious Diseases Society of America: http://www.idsociety.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Bone marrow grafts have helped both patients stay all but virus-free for three years. But the disease has come back before in others, and a simpler treatment is needed
Low levels of alcohol can improve your ability to discriminate between different odours, but be warned, the effect is reversed if you drink too much
Modified mozzies will be raised and released on a commercial scale for the first time, but critics warn that this biotech has not been sufficiently tested
Locally acquired cases of chikungunya virus have been identified in the US for the first time, while cases soar in Europe and Central America
A significant percentage of obese kids think their weight is just fine. But do they need to know the truth to get healthier?
Cancer-fighting drug romidepsin has been shown to expose hibernating HIV, making it susceptible to attack
Oversleep causes a feeling similar to feeling hung over and it's caused by the same biological function that gives you jet lag.
Early results of a drug combination called PaMZ offer the best hope in decades of bringing the pernicious, drug-resistant form of tuberculosis under control
The U.S. Centers for Disease Control and Prevention "may never know" how a fairly harmless form of bird flu was cross-contaminated with a dangerous bird flu strain before it was sent to a laboratory outside of the CDC, an agency spokesman said on Monday.
A group of seven leading drugmakers has agreed to share an array of neglected experimental medicines with British academic researchers in the latest example of the deepening ties between industry and external scientists.